Frontlight ResearchEarly access
Not yet taking people in United StatesPhase 3
Fighting Osteoporosis With Risedronate Co-Therapy During Incretin
Key facts
- Who runs it
- Wake Forest University Health Sciences
- Where
- Winston-Salem, United StatesSee the site
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 3
- People taking part
- 96 people, planned
- Starts
- Jun 2027
- Expected to end
- Nov 2031
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Tirzepatide
- Risedronate
- Placebo
- Record updated
- 17 November 2026
Who can take part
- Age
- 60 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- BMI≥30 or 27.0-29.9 kg/m2 plus one weight related co-morbidity
- Weight stability (within 5% in past 3 months)
- Community dwelling
- English speaking
- Able to attend regular in person appointments, willingness to take tirzepatide and risedronate medication, and willing to provide informed consent
Who cannot take part
- >1 fall (injurious or non-injurious) in past year or prior fragility fracture
- Osteoporosis (self-report, medication use, or T-score ≤ -2.5 on hip or spine DXA scan)
- Use of oral corticosteroids (>5 d/month in past 3 months), use of incretin analog (GLP1Ra or dual agonist) in past 24 months, use of any AOM or prescription osteoporosis medication in last 12 months, history of intolerance or adverse reaction to GLP1Ra (other incretin analog) or bisphosphonate, concomitant use of insulin secretagogues or insulin
- Eating disorder in past 5 years
- Weight >450 lbs (DXA limit)
- Disordered alcohol or substance use
Where in United States
- Atrium Health Wake Forest BaptistWinston-Salem, United StatesContact: Kim KennedyNot yet recruiting
About the trial
What the trial wants to find out
Tirzepatide produces rapid, clinically meaningful weight loss. In older adults, however, substantial weight reduction may accelerate loss of bone and muscle, increase frailty risk, and compound age-related skeletal vulnerability. The purpose of this study is to find out if taking risedronate along with tirzepatide preserves musculoskeletal health during tirzepatide-associated weight loss.
The 2 groups in the trial
- Tirzepatide Plus RisedronateTreatment being tested
Treatment: Tirzepatide and Risedronate
- Tirzepatide Plus PlaceboExisting treatment, for comparison
Treatment: Tirzepatide and Placebo
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Bisphosphonate Co-Therapy to Preserve Musculoskeletal Health in Older Adults Using Tirzepatide
- Record updated
- 17 November 2026